Contact
- Division Director, Cancer Biology (Interim)
- Associate Director, Translational Research
- Professor
233 S. 10th Street
BLSB, Suite 1006
Philadelphia, PA 19107
- 215-503-9943
- 215-503-1161 (lab)
Highlighted Publications
Liao Z, Gu L, Vergalli J, Mariani SA, De Dominici M, Lokareddy RK, Dagvadorj A, Purushottamachar P, McCue PA, Trabulsi E, Lallas CD, Gupta S, Ellsworth E, Blackmon S, Ertel A, Fortina P, Leiby B, Xia G, Rui H, Hoang DT, Gomella LG, Cingolani G, Njar V, Pattabiraman N, Calabretta B, Nevalainen MT. Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics (AACR). 2015 Aug;14(8):1777-93 PMCID: PMC4547362. Highlighted article and cover of the August 2015 issue.
Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. Am J Pathol. 2015 Sep;185(9):2505-22 PMCID: PMC4597281. Subject of an Editorial.
Hoang DT Iczkowski KA, Kilari D, See W, Nevalainen MT; Androgen Receptor-Dependent and -Independent Mechanisms Driving Prostate Cancer Progression: Opportunities for Therapeutic Targeting from Multiple Angles. Oncotarget2017 Jan 10, 8(2) 3724-3745. PMCID: PMC5356914.
Bassem R. Haddad, Andrew Erickson, Vindhya Udhane, Peter LaViolette, Janice D. Rone, Markku Kallajoki, William See, Antti Rannikko, Tuomas Mirtti, Marja T. Nevalainen. Positive STAT5 Protein and Locus Amplification Status Predicts Prostate Cancer Recurrence After Radical Prostatectomy to Assist Precision Medicine of Prostate Cancer. Cancer Epidemiology, Biomarkers and Prevention (AACR). 2019 Oct;28(10):1642-1651. PMCID: PMC6774884.
Vindhya Udhane, Cristina Maranto, David T. Hoang, Lei Gu, Andrew Erickson, Savita Devi, Pooja G. Talati, Anjishnu Banerjee, Kenneth Iczkowski, Kenneth Jacobsohn, William See, Tuomas Mirtti, Deepak Kilari, Marja T. Nevalainen. Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors. Molecular Cancer Therapeutics (AACR). 2020 Jan;19(1):231-246. PMCID: PMC6946850.
Maranto C, Udhane V, Jing J, Verma RS, Fahrenkamp D, Muller-Newen G, LaViolette PS, Pereckas M, Sabharwal L, Terhune S, Pattabiraman N, Njar VCO, Imig JD, Wang L, Nevalainen MT. Prospects for clinical development of Stat5 inhibitor IST5-002: High transcriptomic specificity in prostate cancer and low toxicity in vivo. Cancers (Basel), 2020 Nov18;12(11):3412.doi.10.3390/cancers12113412. PMCID: PMC7724566.
Beinhoff P, Maranto C, Udhane V, Sabharwal L, See W, Jacobsohn K, Iczkowski K, Hall W, Kilari D, Nevalainen MT. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development? Invited Review, Cancers (Basel), 2021 Oct 17; 13(20):5204. PMCID: PMC8533841
Maranto C*, Udhane VU*, Sabharwal L*, Pitzen S, McCluskey B, Devi S, Johnson S, Jacobsohn K, Banerjee A, Iczkowksi KA, Wang L, Dehm S, Nevalainen MT. Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target androgen receptor signaling. In Revision, Science Advances, 2023.
Publications
- Stat5 induces androgen receptor (AR) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling
- Changes in Daily Apparent Diffusion Coefficient on Fully Quantitative Magnetic Resonance Imaging Correlate With Established Genomic Pathways of Radiation Sensitivity and Reveal Novel Biologic Associations
- Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness
- Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer
- Second-generation jak2 inhibitors for advanced prostate cancer: Are we ready for clinical development?
- Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology
- NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers
- Prospects for clinical development of stat5 inhibitor IST5-002: High transcriptomic specificity in prostate cancer and low toxicity in vivo
- Cytokines, JAK-STAT Signaling and Radiation-Induced DNA Repair in Solid Tumors: Novel Opportunities for Radiation Therapy
- Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network
- Enzalutamide-induced feed-forward signaling loop promotes therapy-resistant prostate cancer growth providing an exploitable molecular target for JAK2 inhibitors
- Gleason probability maps: A radiomics tool for mapping prostate cancer likelihood in mri space
- Positive STAT5 protein and locus amplification status predicts recurrence after radical prostatectomy to assist clinical precision management of prostate cancer
- Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia
- Radio-pathomic Maps of Epithelium and Lumen Density Predict the Location of High-Grade Prostate Cancer
- STAT5A/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair
- Optimized b -value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging
- ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
- Erratum: ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development
- Jak2/Stat5a/b pathway in prostate cancer